Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Clinical trials sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., explained in plain language.
-
New pill aims to shrink spleens in rare bone marrow cancer
Disease control OngoingThis study tests a new tablet called TQ05105 against a standard drug (hydroxyurea) in 107 adults with moderate or high-risk myelofibrosis, a rare bone marrow disorder. The main goal is to see if TQ05105 can shrink the spleen by at least 35% after 24 weeks of treatment. Participan…
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC
-
New combo therapy shows promise in slowing advanced breast cancer
Disease control OngoingThis phase 3 trial tests whether adding the experimental drug TQB3616 to standard hormone therapy (fulvestrant) can delay cancer growth in people with HR-positive, HER2-negative advanced breast cancer. About 432 participants will receive either the combination or a placebo plus f…
Phase: PHASE3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC
-
New pill shows promise for Hard-to-Treat transplant complication
Disease control OngoingThis study tests an experimental tablet called TQ05105 in 45 adults with moderate to severe chronic graft-versus-host disease (cGVHD) that hasn't improved with steroids. The goal is to find the best dose and see if it can control the disease and ease symptoms. Participants take t…
Phase: PHASE1, PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC